CÁNCER RENAL
BIBLIOGRAFÍA
1 GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. ARCI: MS; [último acceso el 04/02/17]. Accesible en: http://globocan.iarc.fr/Default.aspx.
2 Dutcher JP. Recent developments in the treatment of renal cell carcinoma. Ther. Adv. Urol. 2013;5(6):338- 353
3 Pecuchet N, Fournier LS, Oudard S. New insights into the management of renal cell cancer. Oncology. 2013;84(1):22-31
4 Vineis P, Alavanja M, Buffler P, Fontham E, Franceschi S, Gao YT et al. Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst. 2004; 96 (2): 99-106.
5 Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer 2005; 114(1):101-108.
6 Bergstrom A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer: a quantitative review. Br J Cancer. 2001; 85 (7): 984-90.
7 Shapiro JA, Williams MA, Weiss NS, Stergachis A, LaCroix AZ, Barlow WE. Hypertension, antihypertensive medication use, and risk of renal cell carcinoma. Am J Epidemiol. 1999;149:521–30.
8 Chow WH, Gridley G, Fraumeni JF, Järvholm B. Obesity, hypertension, and the risk of kidney cancer in man. N Engl J Med. 2000;343:1305–11.
9 Dhôte R, Pellicert- Coeuret M, Thiounn N, Debré B, Vidal- Trecan G. Risk factor for adult renal cell carcinoma: a systematic review and implications for prevention. BJU International. 2000, 86: 20-27.
10 Pesch B, Haerting J, Ranft U et al. Occupational risk factors for renal cell carcinoma: agent-specific results from a case-control study in Germany. MURC Study Group. Multicenter urothelial and renal cancer study. Int J Epidemiol, 2000; 29: 1014–1024.
11 Satoh S, Tsuchiya N, Habuchi T, Ishiyama T, Seimo K, Kato T, et al. Renal cell and transitional cell carcinoma in a Japanese population undergoing maintenance dialysis. J Urol. 2005; 174: 1749-1753.
12 Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999; 281: 1628-31.
13 Linehan WM, Schmidt LS. Cancers of the genitourinary system. In de Vita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2008, pp 1315-24.
14 Esteban Gonzalez E, Muriel López C, Sanmamed M, Ferros Fombella JP, Crespo Herrero G. Carcinoma de riñón: epidemiología y prevención. Editado por Ergon. Tratado de tumores genitourinarios. Madrid, 2011, pp 36-41.
15 Störkel S, van den Berg E. Morphological classification of renal cancer. World J Urol 1995; 13: 153-158.
16 Lane BR; Li J, Zhou M, et all: Differential expression in clear cell renal cell carcinoma identified by gene expression profiling. J Urol. 2009; 181: 849-860.
17 Medina Villaamil V, Blanco Clavo M, Aparicio Gallego G, et all: Etiopatogenia, histología y biología molecular del cáncer renal. Editado por Arranz Arrija JA. Tratado de tumores genitourinarios, Madrid, 2011, pp 45-91
18 Leroy X, Zini L, et all: Morphologic subtyping of papillary renal cell carcinoma: correlation with prognosis and differential expression of MUC1 between the two subtypes. Mod Pathol. 2002; 15: 1126-1130
19 Fuhrman SA et al., Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655-63, 1982
20 Vogelzang NJ, Stadler WM. Kidney cancer. Lancet. 1998;352(9141).
21 Marple JT, MacDougall M, Chonko AM. Renal cancer complicating acquired cystic kidney disease. J Am Soc Nephrol. 1994;4:1951–1956.
22 Conde Santos G. Valor pronóstico del tamaño nucleolar en el carcinoma de células renales - estudio mediante morfometría ultraestructural. Departament de cirurgia facultat de medicina universitat autònoma de barcelona 2006.
23 Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernionn JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol. 2000;163:426-30
24 Israel GM, Bosniak MA. How I do it: evaluating renal masses. Radiology 2005 Aug;236(2):441-50.
25 Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 2001 Jul;66(1):6-18.
26 Ferda J, Hora M, Hes O, Ferdová E, Kreuzberg B. two-phase MDCT-angiography. Eur J Radiol 2007 May;62(2):295-301two-phase MDCT-angiography. Eur J Radiol 2007 May;62(2):295-301.
27 Sun MR, Pedrosa I. Magnetic resonance imaging of renal masses. Semin Ultrasound CT MR. 2009 Aug;30(4):326-51
28 Putra LG, Minor TX, Bolton DM, Appu S, Dowling CR, Neerhut GJ. Improved assessment of renal lesions in pregnancy with magnetic resonance imaging. Urology 2009 Sep;74(3):535-9.
29 Park JW, Jo MK, Lee HM. Significance of 18F-fluorodeoxyglucose positron-emission tomography/ computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int 2009 Mar;103(5):615-9.
30 Sheth S, Scatarige JC, Horton KM, Corl FM, Fishman EK. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector CT and three-dimensional CT. Radiographics 2001;21 Spec No:S237-54.
31 Kabala JE, Gillatt DA, Persad RA, Penry JB, Gingell JC, Chadwick D. Magnetic resonance imaging in the staging of renal cell carcinoma. Br J Radiol 1991;64(764):683-9.
32 Gupta NP, Ansari MS, Khaitan A, Sivaramakrishna MS, Hemal AK, Dogra PN, Seth A. Impact of imaging and thrombus level in management of renal cell carcinoma extending to veins. Urol Int 2004;72(2):129-34.
33 Bosniak MA. Problems in the radiologic diagnosis of renal parenchymal tumors. Urologic Clinics of North America. 1993; 20:217-230.
34 Warren KS, McFarlane J. The Bosniak classification of renal cystic masses. BJU Int 2005 May;95(7):939-42.
35 Silverman SG, Gan YU, Mortele KJ, Tuncali K, Cibas ES. Renal masses in the adult patient: the role of percutaneous biopsy. Radiology 2006 Jul:240(1):6-22.
36 Remzi M, Marberger M. Renal tumor biopsies for evaluation of small renal tumors: why, in whom and how? Eur Urol 2009 Feb;55: 359-67.
37 Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6(7):655-63.
38 Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969; 101(3):297-301.
39 Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 479-89.
40 MacLeannan S, Imamura M, Lapitan MC et al. UCAN systematic review reference group: EAU renal cáncer guideline panel. Systematic review of oncological outcomes following surgical management of localized renal cancer. Eur Urol 2012;61:972-993.
41 Lee JH, You CH, Min GE et al. Comparison of the surgical outcome and renal function between radical and nephron-sparing surgery for renal cell carcinomas. Korean J Urol 2007;48:671-676.
42 Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011 Apr;59(4):543-52.
43 Psutka SP, Feldman AS, McDougal WS et al. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur Urol 2013;63:486-492.
44 Jewett MA, Mattar K, Basiuk J et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol 2011;60:39-44.
45 Peng B, Zheng J-H, Xu D-F, Ren J-Z. Retroperitoneal laparoscopic nephrectomy and open nephrectomy for radical treatment of renal cell carcinoma: A comparison of clinical outcomes. Academic Journal of Second Military Medical University 2006;27:1167-9.
46 Gettman MT, Napper C, Corwin TS, Cadeddu JA. Laparoscopic radical nephrectomy: prospective assessment of impact of intact versus fragmental removal on postoperative quality of life. J Endourol 2002 Feb;(1)16:23-6.
47 Simmons MN, Weight CJ, Gill IS. Laparoscopic radical vs. partial nephrectomy for tumors >4 cm: intermediate-term oncologic and functional outcomes. Urology 2009 May;73(5):1077-82.
48 Shekarriz B, Upadhyay J, Shekarriz H, et al. Comparison of costs and complications of radical and partial nephrectomy for treatment of localized renal cell carcinoma. Urology 2002 Feb; 59(2):211-15
49 Poulakis V, Witzsch U, de Vries R, et al. Quality of life after surgery for localized renal cell carcinoma:comparison between radical nephrectomy and nephron-sparing surgery. Urology 2003 Nov;62(5):814-20
50 Lee JH, You CH, Min GE et al. Comparison of the surgical outcome and renal function between radical and nephron-sparing surgery for renal cell carcinomas. Korean J Urol 2007;48:671-676.
51 Medina-Polo J, Romero-Otero J, Rodríguez-Antolín A,et al. Can partial nephrectomy preserve renal function and modify survival in comparison with radical nephrectomy? Scand J Urol Nephrol. 2011 Mar;45(2):143-50
52 Clark PE, Schover LR, Uzzo RG, Hafez KS, Rybicki LA, Novick AC. Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: impact of the amount of remaining renal tissue. Urology 2001;57:252-6.
53 Bekema HJ, MacLennan S, Imamura M, et al. Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. Eur Urol 2013 Nov;64(5):799-810.
54 Capitanio U, Becker F, Blute ML, et al. Lymph node dissection in renal cell carcinoma. Eur Urol 2011 Dec;60(6):1212-20.
55 Kim S, Thompson HR, Weight C, et al. The relationship of lymph node dissection with recurrence and survival for patients treated with nephrectomy for high-risk renal cell carcinoma. J Urol 2012;187(4S):e233.
56 Hutterer GC, Patard JJ, Perrotte P, et al. Patients with renal cell carcinoma nodal metastases can be accurately identified: external validation of a new nomogram. Int J Cancer 2007 Dec;121(11):2556-61
57 Forauer AR, Kent E, Cwikiel W, et al. Selective palliative transcatheter embolization of bony metastases from renal cell carcinoma. Acta Oncol 2007;46(7):1012-18.
58 Haas NB, Manola J, Uzzo RG, Atkins MB, Wilding G y Pins M. Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. J Clin Oncol 33, 2015 (suppl 7; abstr 403).
59 Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal cell carcinoma after nephrectomy. N Engl J Med. 2016; 375:2246-2254
60 Motzer RJ, Haas NB, Donskov F, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT). J Clin Oncol 2017;35(suppl; abstr 4507).
61 Heng et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study The Lancet Oncology - 1 February 2013 ( Vol. 14, Issue 2, Pages 141-148 ) DOI: 10.1016/S1470-2045(12)70559-4
62 Genega EM, Ghebremichael M, Najarian R, Fu Y, Wang Y, Argani P, Grisanzio C, Signoretti S. Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol. 2010;134:873–879.
63 Centro de Información online de Medicamentos de la AEMPS – CIMA. Agencia española de medicamentos y productos sanitarios. Último acceso 04/02/2017. Disponible en: https://www.aemps.gob.es/cima/fichasTecnicas.do?metodo=detalleForm
64 European public assessment reports (EPAR) for human medicines published by the European Medicines Agency (EMA). Fecha de última consulta 04/02/2017. Disponible en: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124
65 Cherny NI, Sullivan R, Dafni U et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547–1573
66 Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995; 13:688-96.
67 Fisher RI, Rosenberg SA, Sznol M et al. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am. 1997; 3:s70-2.
68 Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21:3127.
69 Poust JE, Woolery JE, Green MR. Management of toxicities associated with high-dose interleukin-2 and biochemotherapy. Anticancer Drugs. 2013; 24:1-13.
70 Belldegrun A, Webb DE, Austin HA 3rd, et al. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 1987; 106:817.
71 Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal- cell carcinoma. N Engl J Med 356:115-124, 2007
72 Motzer RJ, Hutson TE, Tomczak ME et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metatatic renal cell carcinoma. J Clin Oncol. 2009; 27:3584-90.
73 Sterberg CN, Davis ID, Mardiak J et al. Pazopanib in locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol. 2010;28;1061-8
74 Motzer RJ, Hutson TE, Cella D et al. Pazopanib versus sunitinib in metastatic renal cell carcinoma. N Engl J Med. 2013; 369:722-31.
75 Bernard J. Escudier, Camillo Porta et al Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)-PISCES study, NCT 01064310. J Clin Oncol 30, 2012 (suppl; abstr CRA4502)
76 Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356:2271-81.
77 Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB et al. Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol 2014; 32:760-767.
78 Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet. 2007; 370:2103-11.
79 Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008; 26:5422-8.
80 Escudier B, Bellmunt J, Negrier S et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010; 28:2144-50.
81 Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010; 28: 2137-43.
82 Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010; 116: 4256-65.
83 Rugo H, Seneviratne L, Beck J, et al: Prevention of everolimus/exemestane stomatitis in postmenopausal women with hormone receptor–positive metastatic breast cancer using a dexamethasone-based mouthwash: Results of the SWISH trial. MASCC/ISOO International Symposium on Supportive Care in Cancer. Abstract MASCC-0638. Presented June 23, 2016.
84 Escudier B, Eisen T, Stadler WN et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009; 27:3274-76.
85 Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus Sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378:1931.
86 Choueiri TK, Escudier B et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Jul;17(7):917-27.
87 Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol 2016 November 14 (Epub ahead of print).
88 http://gruposdetrabajo.sefh.es/genesis/genesis/Enlaces/InformesHosp_abc.htm
89 Calvo Aller E., Maroto P. et al. Cost- effectiveness evaluation of sunitinib as firs- line targeted therapy for metastatic renal cell carcinoma in Spain. Clin Trans Oncol. 2011 Dec; 13(12): 869-77.
90 Villa G., Hernández-Pastor LJ. Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain. BMC Cancer 2013,13:399
91 Hansen RN, Hackshaw MD, Nagar Sp et al. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Spec Pharm 2015 Jan; 21(1): 37-44
92 Hoyle M, Green C, Thompson-Coon J, Liu Z, Welch K, Moxham T, Stein K. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.Value Health. 2010 Jan-Feb;13(1):55-60.
93 NICE. Nivolumab for previously treated advanced renal cell carcinoma. Technology appraisal guidance [TA417] Published date: 23 November 2016 Last updated: 07 November 2017. https://www.nice.org.uk/guidance/GID-TA10037/documents/appraisal-consultation-document. Disponible en: https://www.nice.org.uk/guidance/ta417/chapter/4-Committee-discussion#cost-effectiveness
94 Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann Oncol. 2012 Sep;23 Suppl 8:viii35-40.
95 Rini BI, Stenzl A, Zdrojowy R, et al: IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): A multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 17:1599-1611, 2016.
96 Amin A, Dudek AZ, Logan TF, et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J Immunother Cancer 2015; 3: 14
97 Lamers CHJ, Klaver Y, Gratama JW, Sleijfe S, Debets R. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells- a completed study overview. Biochem Soc Trans 2016;44:951–959.
98 Yang JC1, Hughes M, Kammula U, Royal R, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007 Nov-Dec;30(8):825-30.
99 Motzer RJ, Powles T, Atkins MB et al. IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). J Clin Oncol 36, 2018 (suppl 6S; abstr 578)
100 Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–13
101 Cella D, Grunwald V, Nathan P, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in Mate 025: a randomised, open-label, phase 3 trial. Lancet Oncol 2016; 17 (7): 994–1003.
102 Sharma P, Tykodi SS, Escudier B, et al. Three-Year Efficacy and Safety Update From the Phase III CheckMate 025 Study of Nivolumab Versus Everolimus in Patients With Advanced Renal Cell Carcinoma. Poster presented at at the 16th International Kidney Cancer Symposium; November 3–4, 2017; Miami, FL, USA.
103 Escudier B. Tannir N, McDermott DF, et al: CheckMate 214: Efficacy and safety of nivolumab + ipilimumab v sunitinib for treatment-naive advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups. ESMO 2017 Congress. Abstract LBA5. Presented September 10, 2017.
104 Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. BJC (2017) 116, 1558–1563. doi:10.1038/bjc.2017.142 Published online 18 May 2017.
105 British Cancer Columbia Agency. Fecha de última consulta 11/06/2017. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Nivolumab_handout_1Mar2017.pdf
106 Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412–20.
107 Mizuki N. et al. Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements. Clin Cancer Res July 15, 2013 19; 3936.
108 Seymour, Lesley et al.iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet Oncology , Volume 18 , Issue 3 , e143 - e152
109 Blank CU, Haanen JB, Ribas A, Schumacher TN. Cancer immunology. The “cancer immunogram”. Science (2016) 352(6286):658–60.10.1126/science.aaf2834